*EMBARGOED All research presented at the 2023 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 22, 2023, at 3:00 pm PT.
P2613 – Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study
Monday, October 23, 2023 | 10:30 AM – 4:15 PM PT | Location: Exhibit Hall
Author Insight from Wissam Ghusn, MD (pictured) & Andres Acosta, MD, PhD, Mayo Clinic, Rochester, MN
What’s new here and important for clinicians?
In this study, we show that the use of semaglutide for obesity results in significant weight loss outcomes and decreases the atherosclerosis cardiovascular disease risk of patients with obesity. Considering the fact that patients with obesity are more prone to develop cardiovascular diseases, this medication is able to target both of obesity and cardiovascular health, improving health care outcomes in terms of morbidity and mortality.
What do patients need to know?
Patients with obesity are at higher risk of cardiovascular diseases, which is among the most common causes of death, worldwide. Patients may reduce their cardiovascular disease risk if they use semaglutide for weight loss. This medication may be able to help them reach their goal weight and improve their cardiovascular health.
Author Contacts
Wissam Ghusn, MD & Andres Acosta, MD, PhD, MD, Mayo Clinic, Rochester, MN
wissamghusn7 [at] gmail.com & acosta.andres [at] mayo.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.